(XBI) SPDR S&P Biotech - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US78464A8707 • Health
XBI: Pharmaceuticals, Biologic Drugs, Research, Development
The SPDR® S&P Biotech ETF (XBI) is designed to replicate the performance of the S&P Biotechnology Select Industry Index, which is a subset of the S&P Total Market Index (S&P TMI). The fund utilizes a sampling strategy to achieve its investment objective, typically allocating 80% to 100% of its assets to securities included in the index. This index focuses on companies in the biotechnology sector, offering exposure to a broad range of firms involved in biotech research, development, and production. The ETF provides investors with a cost-effective way to gain diversified exposure to the biotechnology industry, which is known for its high growth potential but also its volatility.
As of the latest data, XBI has an average trading volume of 14,066,400 shares over the past 20 days, with a last price of $80.25. Its short-term moving average (SMA 20) stands at $76.86, while the medium-term SMA 50 is at $83.58. The long-term SMA 200 is at $93.33, indicating a recent downtrend. The Average True Range (ATR) of $3.14 reflects moderate volatility. The fund manages assets under management (AUM) of $4,751.05 million, making it a significant player in the biotech ETF space.
Additional Sources for XBI ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
XBI ETF Overview
Market Cap in USD | 4,839m |
Category | Health |
TER | 0.35% |
IPO / Inception | 2006-01-31 |
XBI ETF Ratings
Growth Rating | -40.9 |
Fundamental | - |
Dividend Rating | 1.0 |
Rel. Strength | -25.7 |
Analysts | - |
Fair Price Momentum | 63.87 USD |
Fair Price DCF | - |
XBI Dividends
Dividend Yield 12m | 0.16% |
Yield on Cost 5y | 0.13% |
Annual Growth 5y | -13.96% |
Payout Consistency | 38.8% |
XBI Growth Ratios
Growth Correlation 3m | -77.9% |
Growth Correlation 12m | -58.5% |
Growth Correlation 5y | -54% |
CAGR 5y | -5.91% |
CAGR/Max DD 5y | -0.09 |
Sharpe Ratio 12m | 0.58 |
Alpha | -29.47 |
Beta | 1.057 |
Volatility | 43.07% |
Current Volume | 11084.7k |
Average Volume 20d | 11370.9k |
As of May 16, 2025, the stock is trading at USD 77.58 with a total of 11,084,668 shares traded.
Over the past week, the price has changed by -0.59%, over one month by +1.36%, over three months by -15.05% and over the past year by -16.10%.
Probably not. Based on ValueRay Analyses, SPDR S&P Biotech (NYSE ARCA:XBI) is currently (May 2025) not a good stock to buy. It has a ValueRay Growth Rating of -40.85 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of XBI as of May 2025 is 63.87. This means that XBI is currently overvalued and has a potential downside of -17.67%.
SPDR S&P Biotech has no consensus analysts rating.
According to ValueRays Forecast Model, XBI SPDR S&P Biotech will be worth about 74.3 in May 2026. The stock is currently trading at 77.58. This means that the stock has a potential downside of -4.28%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 74.3 | -4.3% |